Digital evolution for ground-breaking Yellow Card Scheme
14 July 2015 | By Victoria White
Fifty years on from its inception, the UK Yellow Card Scheme is moving into the digital age through a free-access mobile app...
List view / Grid view
News
Soliris could drive myasthenia gravis treatment market value beyond $550 million by 2024, says GlobalData
14 July 2015 | By Victoria White
The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024...
EU approves Gadovist for use in paediatric patients less than 2 years of age
14 July 2015 | By Victoria White
Bayer's Gadovist has received a label extension in the EU for diagnostic use with MRI or MRA in paediatric patients less than 2 years of age...
Sanofi Pasteur ships first 2015-2016 seasonal influenza vaccine doses in US
14 July 2015 | By Victoria White
The FDA has released the first doses of Sanofi Pasteur’s Fluzone influenza vaccine for shipment for the 2015-2016 influenza season in the US...
Quotient Clinical acquires second GMP manufacturing facility
14 July 2015 | By Victoria White
Quotient Clinical is to expand its pharmaceutical sciences capabilities. This includes the acquisition of a second GMP manufacturing facility...
Ferrer initiates Phase IIa clinical study of Lorediplon in patients with insomnia
14 July 2015 | By Victoria White
The first patient has been recruited into a Phase IIa clinical trial to test the efficacy, safety and tolerability profile of Lorediplon in insomnia...
FDA approves Iressa for first-line treatment of patients with a type of metastatic lung cancer
14 July 2015 | By Victoria White
The FDA has approved Iressa for the first-line treatment of patients with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations...
pSivida announces positive top-line results from investigator-sponsored Phase II study of Medidur in uveitis
13 July 2015 | By Victoria White
pSivida has announced positive top-line results from a Phase II investigator-sponsored study of Medidur for uveitis affecting the posterior of the eye...
Anacor’s crisaborole achieves primary and secondary endpoints in two Phase 3 studies in eczema
13 July 2015 | By Victoria White
Anacor has announced positive preliminary top-line results from its two Phase 3 pivotal studies of crisaborole in atopic dermatitis (eczema)...
Yusen Logistics expands air freight forwarding operations in Mexico
Yusen Logistics (Mexico) S.A. DE C.V. opened two offices inside and outside at the Mexico City Airport on June 1. By establishing a base on the airport front lines to manage its own air transportation operations, the company aims to realize competitive freight procurement and detailed transportation management of imported…
NICE recommends Lixiana for treating and preventing potentially fatal blood clots
13 July 2015 | By Victoria White
NICE has recommended anti-blood clotting drug Lixiana as an option for treating and preventing the recurrence of potentially fatal blood clots...
Novo Nordisk announces positive results from Phase 3a trial of semaglutide in people with type 2 diabetes
13 July 2015 | By Victoria White
Novo Nordisk has released headline results from SUSTAIN1, the first Phase 3a trial for semaglutide, a GLP-1 analogue administered once-weekly...
Atezolizumab shrank tumours in people with a specific type of bladder cancer in Phase II study
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
SMC accepts sorafenib for use in Scotland
13 July 2015 | By Victoria White
The SMC has announced that sorafenib has been accepted for use within NHS Scotland for the treatment of patients with thyroid carcinoma...
Janssen’s ibrutinib approved by the EC for the treatment of Waldenström’s macroglobulinemia
10 July 2015 | By Victoria White
Janssen-Cilag International announced today that the European Commission (EC) has approved Imbruvica® (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM).
